IgniteData to deploy EHR-to-EDC automation tool in Phase III trial at MSK [Yahoo! Finance]
AstraZeneca PLC - American Depositary Shares (AZN)
Last astrazeneca plc - american depositary shares earnings: 2/5 04:00 pm
Check Earnings Report
US:NYSE Investor Relations:
astrazeneca.com/investor-relations.html
Company Research
Source: Yahoo! Finance
of electronic health record (EHR)-to-electronic data capture (EDC) in a Phase III trial at MSK. This initiative comes after a pilot programme, and it showcases the tool's ability to streamline trials by enhancing accuracy and speed. By the secure transfer of data from hospital EHRs directly to sponsor EDCs, the Archer platform removes the necessity for manually entering the data. This automation allows data to be gathered more swiftly and with minimal errors, enabling researchers to dedicate extra time to progressing clinical science while upholding subject privacy and data integrity. MSK Clinical Research Information Technology senior director Joe Lengfellner said: “The IgniteData Archer platform continues to improve the speed and quality of our data collection across clinical trials. “The implementation of Archer in this AstraZeneca-sponsored Phase III study demonstrates the growing industry-academia alignment on the future of trial data management. This convergence will a
Show less
Read more
Impact Snapshot
Event Time:
AZN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AZN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AZN alerts
High impacting AstraZeneca PLC - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
AZN
News
- When Wall Street Rotates, Biotech Innovators Emerge: The Untapped Opportunities in Oncology [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- KDA GROUP ANNOUNCES A COLLABORATION TO INTEGRATE NEW CLINICAL ALERTS INTO THE MEDHERIZE PLATFORM TO SUPPORT THE ADOPTION OF NEXT-GENERATION SEQUENCING FOR BREAST CANCER PATIENTS [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- KDA GROUP ANNOUNCES A COLLABORATION TO INTEGRATE NEW CLINICAL ALERTS INTO THE MEDHERIZE PLATFORM TO SUPPORT THE ADOPTION OF NEXT-GENERATION SEQUENCING FOR BREAST CANCER PATIENTS [Yahoo! Finance]Yahoo! Finance
- ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Breakthrough Therapy Designation in the US as post-neoadjuvant therapy for patients with HER2-positive early breast cancer [Yahoo! Finance]Yahoo! Finance
- ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Breakthrough Therapy Designation in the US as post-neoadjuvant therapy for patients with HER2-positive early breast cancerBusiness Wire
AZN
Sec Filings
- 12/22/25 - Form 6-K
- 12/22/25 - Form 6-K
- 12/22/25 - Form 6-K
- AZN's page on the SEC website